盆腔放疗联合化疗对新诊断IVB期宫颈癌生存的影响
日本多中心回顾性研究纳入343例新诊断IVB期宫颈癌患者,比较化疗联合盆腔放疗与单纯化疗。倾向性评分匹配后,联合放疗组中位总生存25.0个月 vs 18.0个月(HR 0.58,95%CI 0.42-0.79,p<0.001),无进展生存亦显著改善(HR 0.65,95%CI 0.48-0.87,p=0.002)。
要点
- 匹配后联合放疗组中位OS 25.0个月,单纯化疗组18.0个月,HR 0.58。
- 联合放疗组PFS显著改善,HR 0.65(95%CI 0.48-0.87,p=0.002)。
- 联合放疗组≥3级胃肠道毒性更常见,近距离治疗与OS改善独立相关。
核心结论
- 在选定IVB期宫颈癌患者中,根治剂量盆腔放疗联合化疗与生存改善相关。
- 需前瞻性随机试验验证该回顾性研究结果。
研究设计与样本
- 日本多中心回顾性研究,纳入2016至2020年新诊断FIGO 2018 IVB期宫颈癌患者343例。
- 患者分为单纯化疗组(CT组)和化疗联合盆腔放疗组(PRT组),采用倾向性评分匹配年龄、组织学、T分期、N分期、转移模式和转移灶数量。
- 主要终点为总生存(OS),次要终点为无进展生存(PFS)和晚期不良事件。
主要发现
- 倾向性评分匹配后,PRT组中位OS为25.0个月,CT组为18.0个月(HR 0.58,95%CI 0.42-0.79,p<0.001)。
- PRT组PFS显著改善(HR 0.65,95%CI 0.48-0.87,p=0.002)。
- PRT组OS延长在各转移模式中均可见,但在早期T分期(≤T2)中不明显。
- PRT组中近距离治疗与OS改善独立相关。
- PRT组≥3级胃肠道毒性更常见。
临床怎么用
- 对选定IVB期宫颈癌患者,可考虑根治剂量盆腔放疗联合化疗以改善生存。
- 联合放疗时需关注≥3级胃肠道毒性风险。
- 近距离治疗可能为联合放疗组OS改善的独立相关因素。
局限性
- 本研究为回顾性研究,存在选择偏倚可能。
- 结论需前瞻性随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the survival benefit of adding pelvic radiotherapy (RT) to chemotherapy and to identify patient subgroups most likely to benefit from pelvic RT. MATERIALS AND METHODS: A multicentre retrospective study was conducted in Japan and included patients with newly diagnosed stage IVB (FIGO 2018) cervical cancer treated with chemotherapy alone or chemotherapy plus pelvic RT between 2016 and 2020. Patients were classified into the CT group (chemotherapy-alone) or PRT group (chemotherapy plus pelvic RT). Propensity score matching (PSM) was applied using age, histology, T stage, N stage, metastatic pattern, and number of metastatic lesions. Overall survival (OS) represented the primary endpoint; progression-free survival (PFS) and late adverse events constituted the secondary endpoints. RESULTS: Among 343 patients, the PRT group showed significantly longer OS than the CT group following PSM (median OS: 25.0 vs. 18.0 months; hazard ratio [HR], 0.58; 95% confidence intervals [CI], 0.42-0.79; p < 0.001). PFS was also significantly improved in the PRT group (HR, 0.65; 95% CI, 0.48-0.87; p = 0.002). The longer OS in the PRT group was seen across metastatic patterns, although this was less evident in early T stages (≤ T2). Brachytherapy was independently associated with improved OS in the PRT group. Grade ≥ 3 gastrointestinal toxicity was more frequent in the PRT group. CONCLUSION: In this nationwide, real-world study, definitive-dose pelvic RT combined with chemotherapy was associated with improved survival in selected patients with stage IVB cervical cancer. Prospective randomised trials are warranted to validate these findings.
引用
- Tsuchida K, Ogawa K, Toita T, et al. Survival impact of pelvic radiotherapy plus chemotherapy in newly diagnosed stage IVB cervical cancer in Japan (JROSG22-1/JGOG1088S). Radiother Oncol. 2026. PMID: 42660354. doi:10.1016/j.radonc.2026.111752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。